Literature DB >> 16581333

An assessment of statin safety by hepatologists.

David E Cohen1, Frank A Anania, Naga Chalasani.   

Abstract

The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association's (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581333     DOI: 10.1016/j.amjcard.2005.12.014

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  88 in total

1.  Jaundice due to suspected statin hepatotoxicity: a case series.

Authors:  Ottar M Bergmann; Gudjon Kristjansson; Jon G Jonasson; Einar S Björnsson
Journal:  Dig Dis Sci       Date:  2011-11-11       Impact factor: 3.199

2.  Withholding statins in patients with underlying liver disease: wise or unwise?

Authors:  Robert P Perrillo
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-04

Review 3.  Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Melanie D Beaton
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

Review 4.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Authors:  G Musso; M Cassader; F Rosina; R Gambino
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

Review 5.  Clinical perspective: statins and the liver--harmful or helpful?

Authors:  James H Lewis
Journal:  Dig Dis Sci       Date:  2012-05-12       Impact factor: 3.199

Review 6.  Familial hypercholesterolemia.

Authors:  Victoria Enchia Bouhairie; Anne Carol Goldberg
Journal:  Cardiol Clin       Date:  2015-05       Impact factor: 2.213

Review 7.  Idiosyncratic drug-induced liver injury: a clinical update.

Authors:  Haripriya Maddur; Naga Chalasani
Journal:  Curr Gastroenterol Rep       Date:  2011-02

Review 8.  Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges.

Authors:  Jennifer G Robinson
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  Perceptions of Hepatotoxicity in Medical Therapies.

Authors:  Naga P Chalasani
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-10

10.  Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.

Authors:  Shoba Sujana Kumar; Karen A Lahey; Andrew Day; Stephen A LaHaye
Journal:  Lipids Health Dis       Date:  2009-12-17       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.